Month: August 2024

Company to host conference call on August 15, 2024 at 8:00 a.m. ET BOSTON and ATLANTA, Aug. 14, 2024 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease (“PD”), Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases, today reported financial results for the second quarter ended June 30, 2024 and highlighted recent developments. “The first half of 2024 has showcased the strength of our pipeline through the continued execution of key milestones for both risvodetinib (risvo) and IkT-001Pro,” said Dr. Milton H. Werner, President and Chief Executive Officer of Inhibikase. “We completed enrollment of The 201 Trial evaluating...

Monotherapy activity of long duration in patients who have progressed on checkpoint therapy via a novel immuno-oncology mechanism of action with PD-L1 ETB (MT-6402) program Early indication of monotherapy activity in CTLA-4 ETB (MT-8421) program through T-reg depletion; no drug-related adverse events > grade 2 Novel mechanism of action targeting CD38+ immune cells of B-cell, T-cell, and monocytic lineage representing enhanced potency in I&I without the need for conditioning therapyAUSTIN, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms...

Presented Positive Interim ReSPECT-LM Phase 1 Data for Rhenium (186Re) Obisbemeda for Leptomeningeal MetastasesPresented Positive Topline Clinical Trial Results for CNSide diagnostic in the FORESEE trialManagement to host conference call August 14, 2024 at 5:00 p.m. ET AUSTIN, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced financial results for the second quarter ended June 30, 2024, and provided an overview of recent and upcoming business highlights. Q2 2024 RECENT HIGHLIGHTS AND MILESTONESPresented positive ReSPECT-LM Phase 1 study data at the 2024 Society for NeuroOncology /American Society for Clinical Oncology...

Q4 Total revenues of $164.8 million, an increase of 18% year-over-year, while expanding operating marginsQ4 Recurring revenues of $150.5 million, an increase of 17% year-over-yearFY’24 Total revenues of $654.9 million, an increase of 19% year-over-year, while expanding operating marginsFY’25 revenue guidance of $722.0 – $729.0 million, an increase of 11% year-over-year at the top end of the rangeCINCINNATI, Aug. 14, 2024 (GLOBE NEWSWIRE) — Paycor HCM, Inc. (Nasdaq: PYCR) (“Paycor”), a leading provider of human capital management (“HCM”) software, today announced financial results for the fourth quarter and full fiscal year 2024, which ended June 30, 2024. “Paycor delivered revenue growth of 18% for the quarter and 19% for the year, propelled by strong execution against our strategic growth initiatives to add employees...

Second Quarter 2024US$6.0 billion Total Processed Volume, up 38% year-over-year and 14% quarter-over-quarterRevenue of US$171 million, up 6% year-over-year and down 7% quarter-over-quarter100% Net Revenue Retention RateGross Profit of US$70 million, down 1% year-over-year and up 11% quarter-over-quarterAdjusted EBITDA of US$43 million, down 18% year-over-year and up 16% quarter-over-quarter dLocal reports in US dollars and in accordance with IFRS as issued by the IASB. MONTEVIDEO, Uruguay, Aug. 14, 2024 (GLOBE NEWSWIRE) — DLocal Limited (“dLocal”, “we”, “us”, and “our”) (NASDAQ:DLO), a technology – first payments platform today announced its financial results for the second quarter ended June 30, 2024. We continue to see strong growth in our business, achieving another quarterly record of $6.0 billion of TPV during the second...

HAUPPAUGE, N.Y., Aug. 14, 2024 (GLOBE NEWSWIRE) — AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGW), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private 5G, and other communications networks, including the design of complete 5G/6G systems and a global distributor of packages and lids for integrated circuits assembly, today announced its financial results for the second quarter ended June 30, 2024. The company plans to host an investor call within two weeks after today. Q2 2024 Highlights Revenue of $2.5 million, with gross profits of $1.05M (42%). The company maintained a healthy gross profit margin of approximately 42% amidst inflationary pressures. Significant decrease in global demand and recessionary market dynamics continued to be a factor affecting the majority...

LOS ANGELES, Aug. 14, 2024 (GLOBE NEWSWIRE) — Nova LifeStyle, Inc. (NASDAQ: NVFY) (“Nova LifeStyle” or the “Company”) today announced its financial results for the second quarter ended June 30, 2024. Key Financial Highlights: Operating Results for the Three Months Ended June 30, 2024Net sales for three months ended June 30, 2024 were $2.69 million, a decrease of 40% from $4.46 million in the same period of 2023. Gross profit was $1.19 million compared to $1.45 million in the same period of 2023. Net loss was ($563 thousand), compared to ($539 thousand) loss in the same period of 2023.Operating Results for the Six Months Ended June 30, 2024Net sales for the six months ended June 30, 2024 were $5.06 million, a decrease of 20% from $6.34 million in the same period 2023. Gross profit was $2.21 million, compared to $2.11 million...